PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 27, 2026JEADV Clinical Practice0 citationsOpen Access

Pyoderma Gangrenosum: A Retrospective Cohort Study of Comorbidities and Therapies in Over 65,000 Patients in the TriNetX Database

View Full Paper
RGRhiannon GrangeTSTara SholjiMAMarra Aghajani

Key Points

  • To explore the relationship between pyoderma gangrenosum diagnosis and associated comorbidities, and to analyze treatment sequencing and duration.
  • Retrospective analysis of TriNetX electronic health record network.
  • Identification of pyoderma gangrenosum cases using ICD-10 codes until July 30, 2025.
  • Comorbidities analyzed using McNemar's test; treatment duration assessed via survival analysis.
  • 65,501 pyoderma gangrenosum cases identified.
  • Malignancies were more frequent before PG diagnosis; inflammatory conditions were noted after.
  • Infliximab had the longest median therapy duration at 185 days, while only 2.2% received immunomodulatory therapy first.

Abstract

ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis associated with systemic inflammatory diseases and malignancy. Although biologic therapies demonstrate efficacy in PG, the extent of their real‐world use remains incompletely characterized. Additionally, the temporal relationship between PG and associated comorbidities remains poorly defined. Objectives To examine the temporal relationship between PG diagnosis and associated comorbidities and to describe treatment sequencing and duration of therapies in a large retrospective cohort of PG cases. Methods A retrospective analysis of the TriNetX electronic health record network was performed. Cases of PG were identified using ICD‐10 codes up to July 30, 2025. Comorbidities diagnosed within 10 years before and after PG diagnosis were analyzed using McNemar's test with odds ratios. Treatment duration and switching between therapies were assessed using survival analysis with log‐rank testing. Results A total of 65,501 PG cases were identified. Malignancies were more frequently recorded prior to PG diagnosis, while inflammatory conditions including hidradenitis suppurativa, inflammatory bowel disease and inflammatory arthropathies were more frequently recorded following diagnosis. Antibiotics and corticosteroids were the most commonly recorded first‐line therapies, while only 2.2% of cases were recorded as receiving immunomodulatory therapies initially. The longest median duration of therapy was observed with infliximab (median 185 days), followed by methotrexate (125 days). Conclusions Comorbidity patterns differed before and after PG diagnosis in this large retrospective database analysis. Inflammatory comorbidities were more frequently recorded following PG diagnosis. The uptake of immunomodulatory therapy was low during the study period. These findings should be interpreted cautiously, given the limitations of retrospective database studies and potential diagnostic misclassification, and are best considered hypothesis‐generating.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Grange et al. (2026) studied this question.

synapsesocial.com/papers/69eefdb5fede9185760d469ahttps://doi.org/10.1002/jvc2.70346
Ask AI
Helpful
Bookmark
Share
View Full Paper